135 related articles for article (PubMed ID: 28789399)
21. [Effects of AKT protein kinase activation on biologic behavior of diffuse large B cell lymphoma cells].
Zhang TC; Zhou XY; Yu BH; Zhang TM; Shi DR
Zhonghua Bing Li Xue Za Zhi; 2007 May; 36(5):318-23. PubMed ID: 17706139
[TBL] [Abstract][Full Text] [Related]
22. Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin.
Sun N; Wang CY; Sun YQ; Ruan YJ; Huang YY; Su T; Zhou XH; Huang H; Guo WJ; He MQ; Yao RX; Lin XJ
Biomed Pharmacother; 2018 Oct; 106():267-274. PubMed ID: 29966970
[TBL] [Abstract][Full Text] [Related]
23. [Expression of microRNA-223 and its clinicopathologic correlation in diffuse large B-cell lymphoma].
Yao XX; Wang JF; Wang YH; Gao N
Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):366-70. PubMed ID: 22932402
[TBL] [Abstract][Full Text] [Related]
24. Forkhead box p3 controls progression of oral lichen planus by regulating microRNA-146a.
Wang J; Yang L; Wang L; Yang Y; Wang Y
J Cell Biochem; 2018 Nov; 119(11):8862-8871. PubMed ID: 30125971
[TBL] [Abstract][Full Text] [Related]
25. Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study.
Marchesi F; Regazzo G; Palombi F; Terrenato I; Sacconi A; Spagnuolo M; Donzelli S; Marino M; Ercolani C; Di Benedetto A; Blandino G; Ciliberto G; Mengarelli A; Rizzo MG
J Exp Clin Cancer Res; 2018 May; 37(1):95. PubMed ID: 29716630
[TBL] [Abstract][Full Text] [Related]
26. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195.
Wang QM; Lian GY; Song Y; Huang YF; Gong Y
Life Sci; 2019 Aug; 231():116335. PubMed ID: 30898647
[TBL] [Abstract][Full Text] [Related]
27. [Correlation between FOXP3, CD11c Protein Expression and Prognosis of Patients with Diffuse Large B-cell Lymphoma].
Li YB; Wang Z; Zuo HB; Li LB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):104-108. PubMed ID: 33554805
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-9 promotes cell survival and drug resistance in diffuse large B-cell lymphoma.
Lv X; Feng L; Ge X; Lu K; Wang X
J Exp Clin Cancer Res; 2016 Jul; 35(1):106. PubMed ID: 27364124
[TBL] [Abstract][Full Text] [Related]
29. High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma.
Marques SC; Ranjbar B; Laursen MB; Falgreen S; Bilgrau AE; Bødker JS; Jørgensen LK; Primo MN; Schmitz A; Ettrup MS; Johnsen HE; Bøgsted M; Mikkelsen JG; Dybkær K
Exp Hematol; 2016 Apr; 44(4):238-46.e2. PubMed ID: 26854484
[TBL] [Abstract][Full Text] [Related]
30. [Expression of MiR-155 in Tissue of Patients with Diffuse Large B-Cell Lymphoma and Its Effect on Cell Biological Characteristics].
Han B; Gao ZD; Wang HX; Wang ZH; Fan CB; Liu JL; Tian M; Zhao HG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):445-451. PubMed ID: 30998152
[TBL] [Abstract][Full Text] [Related]
31. Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting.
Romero M; Gapihan G; Castro-Vega LJ; Acevedo A; Wang L; Li ZW; El Bouchtaoui M; Di Benedetto M; Ratajczak P; Feugeas JP; Thieblemont C; Saavedra C; Janin A
Oncotarget; 2017 Mar; 8(10):16243-16258. PubMed ID: 27806315
[TBL] [Abstract][Full Text] [Related]
32. [Expression and clinical significance of miR-21 in diffuse large B cell lymphoma].
Li CH; Fu R; Wang YH; Song WJ; Ruan EB; Qu W; Wang HQ; Wang GJ; Song J; Wang XM; Wu YH; Xing LM; Liu H; Li LJ; Guan J; Shao ZH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):339-43. PubMed ID: 24763002
[TBL] [Abstract][Full Text] [Related]
33. [Mechanism of MiR-224 Affecting DLBCL Cell Proliferation and Invasion by Targeted Inhibition of PIK3CD].
Xie Y; Tan L; Li YT; Zeng Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1578-1584. PubMed ID: 33067957
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma.
Due H; Schönherz AA; Ryø L; Primo MN; Jespersen DS; Thomsen EA; Roug AS; Xiao M; Tan X; Pang Y; Young KH; Bøgsted M; Mikkelsen JG; Dybkær K
Blood Adv; 2019 Apr; 3(7):1185-1196. PubMed ID: 30967394
[TBL] [Abstract][Full Text] [Related]
35. [Relation of MiR-34a Expression in Diffuse Large B Cell Lymphoma with Clinical Prognosis].
Liu YP; Hu H; Xu F; Wen JJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):455-459. PubMed ID: 28446292
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy.
Lee S; Kim DH; Oh SY; Kim SY; Koh MS; Lee JH; Lee S; Kim SH; Kwak JY; Pak MG; Ju MH; Kim HJ; Jeong JS
Korean J Intern Med; 2017 Mar; 32(2):335-344. PubMed ID: 26968188
[TBL] [Abstract][Full Text] [Related]
37. miR-31 and miR-17-5p levels change during transformation of follicular lymphoma.
Thompson MA; Edmonds MD; Liang S; McClintock-Treep S; Wang X; Li S; Eischen CM
Hum Pathol; 2016 Apr; 50():118-26. PubMed ID: 26997445
[TBL] [Abstract][Full Text] [Related]
38. [Expression and Function of miR-181b in Diffuse Large B Cell Lymphoma].
He B; Zhu DX; Chao HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1111-1115. PubMed ID: 30111416
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-181a Inhibits Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Progression by Repressing
Zhu D; Fang C; He W; Wu C; Li X; Wu J
J Oncol; 2019; 2019():9832956. PubMed ID: 31662757
[TBL] [Abstract][Full Text] [Related]
40. Infiltration of effector regulatory T cells predicts poor prognosis of diffuse large B-cell lymphoma, not otherwise specified.
Nakayama S; Yokote T; Akioka T; Hiraoka N; Nishiwaki U; Miyoshi T; Iwaki K; Takayama A; Masuda Y; Hatooka J; Fujimoto M; Nishimura Y; Tsuji M
Blood Adv; 2017 Mar; 1(8):486-493. PubMed ID: 29296965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
